Histone modification as a drug resistance driver in brain tumors

查看全文 作　　者：Guifa [1,2,3]Xi;Barbara Mania-[4]Farnell;Ting [5]Lei;Tadanori [1,3]Tomita 机构地区：[1]Falk Brain Tumor Center,Division of Pediatric Neurosurgery,Ann & Robert H.Lurie Children’s Hospital of Chicago,Northwestern University Feinberg School of Medicine;[2]Development Biology Program,Stanley Manne Children’s Research Institute,Ann & Robert H.Lurie Children’s Hospital of Chicago,Northwestern University Feinberg School of Medicine;[3]Department of Neurological Surgery,Northwestern University Feinberg School of Medicine;[4]Department of Biological Sciences,Purdue University Calumet;[5]Department of Neurosurgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology 出　　处：《Oncology and Translational Medicine》索引2016年第2卷第5期,共11页 基　　金：Supported by the Rory David Deutsch Foundation;the Surgical Neuro-oncology Research Fund of Ann&Robert H Lurie Children’s Hospital(A&RLCH) of Chicago;the Dr.Ralph and Marian C.Falk Medical Research Trust 摘　　要：Patients with brain tumors,specifically,malignant forms such as glioblastoma,medulloblastoma and ependymoma,exhibit dismal survival rates despite advances in treatment strategies.Chemotherapeutics,the primary adjuvant treatment for human brain tumors following surgery,commonly lack efficacy due to either intrinsic or acquired drug resistance.New treatments targeting epigenetic factors are being explored.Post-translational histone modification provides a critical regulatory platform for processes such as chromosome condensation and segregation,apoptosis,gene transcription,and DNA replication and repair.This work reviews how aberrant histone modifications and alterations in histone-modifying enzymes can drive the acquisition of drug resistance in brain tumors.Elucidating these mechanisms should lead to new treatments for overcoming drug resistance. 关 键 词：组蛋白修饰 化疗药物 脑肿瘤 耐药性 驱动器 辅助治疗 DNA复制 肿瘤患者